Purpose We aimed to assess the IOPlowering effect of trabeculectomy with ologen in refractory secondary glaucoma following failed trabeculectomy with mitomycin C
Introduction
Trabeculectomy is the most commonly used surgery for lowering intraocular pressure (IOP) by providing a passage to the subconjunctival space. However, the success rate of this surgery has been limited by postoperative fibroblast proliferation and scarring of the filtering bleb. 1 Numerous adjunctive modifications, such as antimetabolites, 2 b-radiation, 3 and anti-VEGF agents, 4 have been developed to prevent scarring.
High-risk factors that lead to the failure of trabeculectomy include previous ocular surgery, specific types of glaucoma, for example, secondary glaucoma such as neovascular, uveitic, post-traumatic, and lens-induced glaucoma. 5 Ologen is a biodegradable, porous, porcine, collagen implant. It influences the fibrosis process by guiding the patterns of fibroblast migration and normalizing secreted extracelluar matrix deposition. It also helps to separate the conjunctiva and episcleral surface preventing adhesions between them. 6 Most of the studies have compared between ologen and mitomycin C (MMC) in primary glaucoma or in primary and secondary glaucomas collectively. Also, studies stated that there was no difference in the success rate between trabeculectomy in cases of open angle and angle closure glaucoma. 7 So, in this work, we aimed to assess the IOP-lowering effect of trabeculectomy with ologen implant in cases of refractory secondary glaucoma following failed trabeculectomy with MMC as well as to compare its surgical outcome between open angle and angle closure cases.
The interesting points in our study were; is trabeculectomy with ologen implant effective in lowering IOP as the well established effect of trabeculectomy with MMC?, is there a difference in IOP reduction between the open angle and the angle closure glaucoma?, can ologen be a better alternative than MMC as a wound modulating agent in glaucoma surgeries?
Materials and methods
Approval for the study was obtained from the hospital's Ophthalmology Department Ethical Committee (according to the WMA Declaration of Helsinki Principle). All patients received a thorough explanation of the study design and aims, and were provided with written informed consent. This is a prospective interventional comparative study conducted on 40 eyes of 40 patients with medically uncontrolled secondary glaucoma, following previously failed trabeculectomy with MMC (0.4 mg/cc for 2 min), and three attempts of needling with 1 month apart. Trabeculectomy with ologen implant was done 1 month after the last needling procedure.
All eyes had IOP above 21 mmHg with the maximally tolerated anti-glaucoma medications (either due to side effects caused by adding more medications or due to extra cost of medications), glaucomatous visual field defects confirmed by 24-2 SITA Standard Humphrey visual field analysis and glaucomatous optic cupping. The study was performed during the time period from July 2013 to July 2014.
All eligible patients from Kasr Al-Ainy Cairo University Hospitals Ophthalmology Department Glaucoma outpatient clinic entered the study consecutively. Kasr Al-Ainy hospital is a central university hospital in Cairo and it is the center for referral from most of the governorates in Egypt.
The patients were divided into two groups; group A: 18 eyes of 18 patients with secondary open angle glaucoma (SOAG), and group B: 22 eyes of 22 patients with secondary angle closure glaucoma (SACG). SOAG is defined as glaucoma with open anterior chamber angle on gonioscopy, in the presence of an identifiable cause resulting in elevation of the IOP, while SACG is defined as the presence of an occludable angle on gonioscopy (posterior trabecular meshwork not seen in at least 180°of the total circumference of the angle in primary position), with an identifiable cause leading to angle closure and elevation of IOP.
Two eyes with media opacities interfering with visual field testing and optical coherence tomography (OCT) imaging were excluded from the study; one eye had corneal opacities and the other had dense cataract requiring combined phacotrabeculectomy with ologen implant. Furthermore, one eye was excluded because the patient had not completed the 12 months of follow-up, and one more because the patient had undergone prior retinal segment surgery. None of the patients had previous anterior segment surgery except for the previous failed trabeculectomy. None of the eyes developed postoperative cataract following trabeculectomy with ologen implant. In all eyes with neovascular glaucoma, the retinal condition was treated and stabilized before the previous failed trabeculectomy by panretinal photocoagulation and nothing was needed regarding the retinal condition.
Preoperative evaluation
All the patients received complete ophthalmological examination, including; measurement of the bestcorrected visual acuity (BCVA), slit lamp examination (studying the old scleral bleb according to Moorfields bleb grading system), IOP measurement with Goldmann's applanation tonometry, dilated fundus examination, and gonioscopy for angle grading using Schaffer's method. The number of anti-glaucoma medications was recorded.
Humphrey SITA standard perimetry (Central 24-2 standard strategy) to assess the field of vision was done. Also spectral domain OCT was done using RTVue Fourier-Domain OCT (v 6.11.0.12, Optovue, Inc., USA) to assess retinal nerve fiber layer (RNFL) thickness. Also, anterior segment OCT (RTVue Fourier-Domain OCT, v 6.11.0.12, Optovue, Inc.) was used to study the old bleb morphology and for confirmation of the type of glaucoma. AS-OCT was done in down gaze to obtain maximal cross sectional exposure. Using a raster scan, AS-OCT (Anterior segment mode using the CAM-L) optical section was obtained that passed through the highest elevation on the surface of the bleb.
Surgical technique
All eyes underwent trabeculectomy with insertion of ologen implant, under peribulbar anesthesia. A fornixbased conjunctival incision was done. A rectangular (4 × 3 mm) superficial scleral flap half of the sclera thickness was fashioned. Paracentesis for gradual decompression was followed by excision of trabecular meshwork block (2 × 1 mm) by Kelly punch, peripheral iridectomy then suturing of the scleral flap using two 10/0 nylon sutures at its corners. The scleral sutures were placed with minimal tension aiming for filtration on minimal pressure and a formed AC at the end of surgery. Ologen (6 mm (D) × 2 mm (H)) was inserted between the posterior sclera and tenon's capsule, resting over the scleral flap. Finally the conjunctiva was sutured with water-tight 10/0 nylon sutures.
Postoperatively, patients were prescribed topical combined antibiotics and steroids eye drops and were instructed for gradual tapering over six weeks. Postoperative cycloplegia was prescribed only when needed.
None of the eyes in either group needed suture lysis, needling with 5FU nor injections of 5FU, and none of the eyes with SOAG needed ALT or SLT.
Postoperative follow-up
All the patients were examined on the first day postoperatively, after 1 week, after 1 month, 6 months, then at 1 year postoperatively. Examination involved measurement of the BCVA, slit lamp examination (for clinical bleb morphology according to Moorfields bleb grading system and postoperative complications), and IOP measurement with Goldmann's applanation tonometry. In addition, Humphrey SITA standard perimetry and OCT (both retinal and anterior segment) were done at 6 months post operatively. Anterior segment OCT was done 6 months postoperatively as the ologen implant was expected to biodegrade after 3-6 months. 8 Also, the number of antiglaucoma medications and the percentage change in the number of medications were recorded.
Surgical success rate was assessed. Complete success was defined as 5 mmHg4IOPo21 mmHg and a relative decrease of ≥ 20% compared with the preoperative IOP, without any additional glaucoma surgery or antiglaucoma medication through all follow-up period. Qualified success was defined as 5 mmHg4IOPo21 mmHg and an additional reduction of ≥ 20% in IOP compared with the preoperative IOP, without any additional glaucoma surgery, but with topical medications. Failure was defined as IOP ≥ 22 mmHg despite maximal medication or IOP ≤ 5 mmHg (on two or more examinations) with hypotony maculopathy or if an additional procedure like needling or repeat trabeculectomy was required to control the IOP or if there was loss of light perception.
Eyes were also assessed according to secondary success rate; number (and percentage) of eyes with IOPo15 mmHg, those 15 mmHg ≥ IOPo18 mmHg and those 18 mmHg ≥ IOP o21 mmHg.
Statistical analysis
Data were statistically described in terms of range, mean ± SD, median frequencies (number of cases), and percentages when appropriate. Comparison of numerical variables between the study groups was done using Mann-Whitney U-test for independent samples, while within group comparison of numerical variables was performed using the Wilcoxon SignedRank test. For comparing categorical data, χ 2 -test was performed. All P-values o0.05 was considered statistically significant. Complete success was analyzed using Kaplan-Meier survival analysis. Predictors of incident glaucoma were examined using multiple linear regression analysis to study their effect on postoperative glaucoma. 
Results
Our study was performed on 40 eyes (40 patients) suffering from SOAG and SACG, requiring glaucoma surgery due to previously failed trabeculectomy.
Patient data
In group A, the patients' mean age was 48.44 ± 3.48 years (with 12 males), while in group B, it was 54.73 ± 2.06 years (with 10 males). Type of glaucoma in each group is shown in Table 1 . All the eyes with angle closure (group B) suffered from synechial angle closure in all quadrants; grade 0 according to Shaffer's classification as detected by indentation gonioscopy using Ziess 4 mirror goniolens.
Preoperative and postoperative BCVA is shown in Table 1 . There was no significant difference between preoperative and postoperative BCVA (P = 1.00) in each group.
The preoperative and postoperative anti-glaucoma medication score is shown in Table 1 . Preoperative medication score compared to postoperative score, in each group was statistically significant (Po0.001). The percentage difference between preoperative and postoperative medication score was compared between both groups and was statistically significant (P = 0.018).
Bleb morphology
Preoperatively, all eyes showed cystic fibrotic scleral bleb due to previously failed trabeculectomy with MMC, while postoperatively they all had new diffuse vascular blebs, as seen clinically (Po0.001 regarding central and peripheral areas, height and vascularity, according to Moorfields bleb grading system) and by the anterior segment OCT (AS-OCT) at 6 months postoperatively (Figure 1a ).
There was a significant difference between group A and B regarding postoperative bleb central and peripheral areas (P = 0.018, and P = 0.001, respectively; Table 2 ).
Intraocular pressure
The preoperative and postoperative IOP measurements at different postoperative visits, the drop and percentage drop in IOP are all shown in Table 3 .
IOP changes in group A were compared with those in group B using Mann-Whitney test. IOP percentage difference was statistically insignificantly different between both groups except at 1 month. (Table 3) Preoperative IOP was compared with postoperative IOP at 1 day, 1 week, 1 month, 6 months, and 1 year, in each group, and was found to be statistically significant (Po0.001 at each follow-up period) using Wilcoxon Signed-Rank test (Figure 1b) .
In group B, six eyes developed IOP421 mmHg; two of them at 3 months and four eyes at 2 months postoperatively. They were all controlled with one antiglaucoma medication. Using multiple linear regression analysis, preoperative medication score (P = 0.030) was a significant risk factor for postoperative glaucoma in group B, while preoperative IOP (P = 0.379) and type of SACG (P = 0.474) were not.
Success rate
In group A, all the eyes achieved complete success (100%), while in group B complete success was 72.7% (P = 0.016). None of the eyes developed hypotony. Also the eyes were graded according to secondary success; IOPo15 mm Hg, 15 mmHg ≥ IOPo18 mmHg and 18 mmHg ≥ IOPo21 mmHg (Table 4 ; Figures 1c and d) .
Visual field changes
Preoperative and postoperative mean deviation (MD) and pattern standard deviation (PSD) and changes in these parameters were recorded (Table 3) .
Comparing group A with group B using MannWhitney test was statistically insignificant except for preoperative PSD (Table 3) .
Also comparing preoperative to postoperative MD and PSD in group A, using Wilcoxon Signed-Rank test, was statistically insignificant (P = 0.085 and P = 0.500, respectively); while in group B, MD significantly differed postoperatively (Po0.001) but PSD did not (P = 0.844; Figures 1e and f) . ± SD) Figure 1g ). Postoperative RNFL thickness did not differ significantly from that preoperatively in group A or B (P = 0.743, P = 0.407, respectively).
Complications
None of the eyes developed intra-or postoperative complications except for one eye which developed a dellen.
Discussion
Trabeculectomy differs from most surgical procedures, as inhibition of wound healing is desirable to achieve surgical success. 9 However, scarring at the episcleral and deep Tenon's level is the main cause of failure of trabeculectomy. Several factors influence and control the complicated mechanism of wound healing. Extracellular matrix components such as collagen and fibronectin, cell adhesion molecules such as selectins and integrins, and different growth factors are intimately involved with the fibroblasts. 10 Several surgical and pharmacologic techniques have been introduced to enhance the success in eyes with poor surgical prognoses. But, no effective and safe agent has been identified that can inhibit fibrosis, without complications, in the glaucoma filtering wound created by trabeculectomy. Although antimetabolites have revolutionized glaucoma surgery, the use of these agents is still associated with substantial risk. 11 Up to our knowledge, this was the first work to highlight the use of ologen implant in cases of secondary glaucoma separately (not in conjunction with primary glaucoma), which represents one of the important risk factors for failure of trabeculectomy. In this work, we also compared the surgical outcome between open angle (SOAG) and angle closure secondary glaucoma (SACG). Many comparative controlled trials have compared the efficacy and tolerability of trabeculectomy augmented with Ologen versus trabeculectomy plus MMC. Some studies have found that the techniques were comparable in IOP-lowering efficacy. [12] [13] [14] [15] Our challenge was to know if the ologen could be better than MMC as a wound modulating agent so nothing could prove this except to put the ologen implant after trabeculectomy in the same eye where the MMC was not efficient.
In a study by Johnson and Sarkisian, 16 they compared outcomes between patients undergoing trabeculectomy with an Ex-PRESS mini glaucoma device using MMC to those undergoing the same procedure using a subconjunctival Ologen, in 99 eyes collectively having primary and secondary open angle and angle closure glaucoma. There was no statistically significant difference between either group for the rates of achieving a specified postoperative IOP either with (qualified success) or without medications. There was no statistically significant difference between the 2 groups in the mean number of postoperative medications required. Both groups had similar rates of complications. 16 In 2015, Ji et al 17 conducted a meta-analysis of randomized clinical trials to assess the efficacy and safety of trabeculectomy with Ologen implant versus trabeculectomy with MMC for treatment of glaucoma. A total of 6 studies including 224 participants were included in this meta-analysis. Ologen implant was associated with a numerically lower but non-significant percentage reduction in IOP compared with MMC. There was no significant difference in the reduction in glaucoma medications, success rate, and incidence of complications. 17 Also, Dada et al 18 evaluated the outcomes of trabeculectomy with use of a subconjunctival Ologen combined with MMC in 33 eyes with primary open angle glaucoma. They declared that it appears to offer encouraging short-term results for IOP control. 18 In a similar study, Min et al 19 studied surgical outcomes and wound healing reaction of a filtering bleb after trabeculectomy using MMC-soaked ologen. They found that it did not exert any synergistic effect in terms of a reduction in IOP, but it resulted in comparatively stable IOP and did not aggravate wound healing or scar formation, while encapsulated blebs were more common and developed more rapidly. 19 In our work, the preoperative IOP was insignificantly different between SOAG (group A) and SACG (group B) glaucoma, while postoperative IOP was significantly lower in each group at each follow up period (Po0.001). The percentage drop in IOP in group A was statistically insignificantly different from that in group B at all follow up periods except at 1 month postoperative when group A percentage drop was significantly more than group B (P = 0.006).
Total success rate (complete+qualified) in our study was 100% in each group. All the eyes (100%) in group A achieved complete success, while 72.7% in group B achieved complete success, with significant difference between both (P = 0.016), as six eyes in group B had their IOP421 mmHg and were controlled with one antiglaucoma medication, which was significantly more than group A (P = 0.024). None of the eyes developed hypotony. Regarding secondary success rate, there was no significant difference between both groups (P = 0.204).
Preoperative medication score was a significant risk factor for postoperative glaucoma, which might explain higher success rate in OAG compared to ACG.
Regarding visual field changes, percentage change in MD and PSD were insignificantly different between both groups. Comparing preoperative to postoperative MD and PSD was statistically insignificant, except for MD in group B which significantly differed postoperatively (Po0.001). RNFL thickness was insignificantly different postoperatively and so was the percentage change in thickness between both groups.
We also studied the filtering scleral bleb in each group clinically and using anterior segment OCT. According to Moorfields bleb grading system; there was a significant difference between group A and B regarding postoperative bleb central and peripheral areas, and a significant difference between preoperative (due to previous failed trabeculectomy) and postoperative bleb morphology in each group. AS-OCT showed that ologen was still present in 100% of the eyes at 6 months, while in a study by Boey et al, 20 it was seen in AS-OCT images in 39.4% of the eyes at 90 days.
In our work, we did not take releasable sutures and also laser suture lysis was not needed and this is one of the advantages of the ologen implant as the scleral sutures could be left not too tight and putting the ologen implant on the posterior edge of the flap can press against the flap. The implant influences the aqueous flow by maintaining pressure on top of the sclera flap and by acting as a reservoir as the aqueous humor is absorbed into its porous structure thus preventing the hypotony and at the same time avoiding the need for removing the sutures. 20 A review of prior studies on the efficacy of Ologen reveals mixed results. Although studies have shown that blebs following the use of Ologen tend to be more vascular and low-lying, there may be a concern that this clinically robust tissue fails to achieve the same IOPlowering effect as the avascular tissue after MMC. 21 In this study, the postoperative medication score differed significantly from the preoperative in each group (Po0.001), and the percentage difference in medication score differed significantly between both groups (P = 0.018).
None of our eyes developed significant complications except for one eye that developed a dellen, due to conjunctival elevation caused by a slightly anteriorly placed ologen. In the study by Dada et al, 18 there were no sight-threatening complications; however, two eyes developed hypotony during the early postoperative course due to leaky conjunctival wound. Another case was noted to have implant exposure at 1 week. Early conjunctival leakage was also reported by Rosentreter et al 21 in 30% of their cases undergoing trabeculectomy with Ologen implantation. This emphasizes that during surgery the conjunctiva should be carefully draped over the implant and closed meticulously to avoid postoperative wound leaks, and the implant should be placed at a slightly posterior position such that it does not impinge on the suture line at the limbus. In the study by Min et al 19 encapsulated blebs occurred in 9 out of 30 eyes among which digital massage was performed on 8 eyes and needling was performed on 1 eye.
To conclude, Ologen may be a useful alternative to MMC in repeat trabeculectomy.
Limitations to our work include; the higher preoperative medication score for ACG which might explain higher success rate with OAG. Also, it was difficult to keep the observers of IOP masked as eyes with SACG might have obvious PAS from the slit lamp evaluation.
Summary
What was known before K Most of the studies have compared between ologen and mitomycin C (MMC) in primary glaucoma or in primary and secondary glaucomas collectively Also, studies stated that there was no difference in the success rate between trabeculectomy in cases of open angle and angle closure glaucoma.
What this study adds K Our results suggest that Ologen may be a useful alternative to MMC in repeat trabeculectomy. 
